Escitalopram
- Generic Name
- Escitalopram
- Brand Names
- Cipralex, Lexapro
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN2O
- CAS Number
- 128196-01-0
- Unique Ingredient Identifier
- 4O4S742ANY
- Background
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...
- Indication
Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...
- Associated Conditions
- Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
- Associated Therapies
- -
Depression, Epinephrine, and Platelet Function
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Emory University
- Target Recruit Count
- 40
- Registration Number
- NCT00166114
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
Escitalopram as a Treatment for Pain in Polyneuropathy
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2007-04-24
- Lead Sponsor
- Odense University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00162968
- Locations
- 🇩🇰
Danish Pain Research Center, Aarhus University Hospital, Noerrebrogade 44, Aarhus, Denmark
🇩🇰Dept. of Neurology, Odense University Hospital, Sdr. Boulevard 29, Odense, Denmark
The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-05-03
- Lead Sponsor
- BeerYaakov Mental Health Center
- Target Recruit Count
- 40
- Registration Number
- NCT00148447
- Locations
- 🇮🇱
Iulian Iancu, Beer Yaakov, Israel
Specific Effects of Escitalopram on Neuroendocrine Response
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2009-02-05
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 8
- Registration Number
- NCT00150527
- Locations
- 🇨🇦
Providence Centre, Mental Health Services, Kingston, Ontario, Canada
Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 30
- Registration Number
- NCT00149825
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT00149799
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Rhode Island Hospital, Providence, Rhode Island, United States
Prevention of Post Traumatic Stress Disorder by Early Treatment
- Conditions
- Interventions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 298
- Registration Number
- NCT00146900
- Locations
- 🇮🇱
Hadassah Medical Organization Jerusalem Israel, Jerusalem, Israel
DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2008-12-31
- Lead Sponsor
- Bispebjerg Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT00140257
- Locations
- 🇩🇰
Bispebjerg University Hospital, Copenhagen, Denmark
Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients
- Conditions
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 208
- Registration Number
- NCT00136318
- Locations
- 🇩🇪
Department of Gastroenterolgy and Rheumatology, Sektion Hepatology, Leipzig, Germany
Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 271
- Registration Number
- NCT00135421
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Albuquerque Neuroscience, Inc., Albuquerque, New Mexico, United States
🇺🇸University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.